Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic

Emerging Infectious Diseases

Volumn 14, Issue 2, 2008, Pages 267-274

  Siddiqui, M Ruby ^a   Edmunds, W John ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; ZANAMIVIR;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG SCREENING; DRUG STORAGE; FATALITY; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; PANDEMIC; QUALITY ADJUSTED LIFE YEAR; SHELF LIFE; UNITED KINGDOM;

EID: 38949158069     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1402.070478     Document Type: Article

References (39)

1. United Kingdom Department of Health. Improving preparedness for possible flu pandemic. 2005 Jan 3 [cited 2005 Feb 10]. Available from http://www.dh.gov.uk
2. United Kingdom Department of Health. Health Department influenza pandemic contingency plan. 2005 [cited 2005 Feb 10]. Available from http://www.dh.gov.uk
3. United Kingdom Office for National Statistics. 2005 Aug 25 [cited 2005 Oct 2]. Available from http://www.statistics.gov.uk
4. Fleming DM. The prediction of epidemics of respiratory infection. Eur J Epidemiol. 1994;10:481-3.
5. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7:iii-xiii, 1.
6. Roche UK. Tamiflu product characteristics. 2006 [cited 2006 Oct 10]. Available from http://www.rocheuk.com
7. Becton Dickinson USA. Directigen. 2005 [cited 2006 Oct 10]. Available from http://www.bd.com
8. Biostar. Biostar Flu OIA. 2005 [cited 2006 Oct 10]. Available from http://www.biostar.com
9. Quidel. QuickVue. 2005 [cited 2006 Oct 10]. Available from http://www.quidel.com
10. Zymetx. Z-Stat Flu. 2005 [cited 2006 Oct 10]. Available from http://www.zymetx.com
11. Chan KH, Maldeis N, Pope W, Yup A, Ozinskas A, Gill J, et al. Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections. J Clin Microbiol. 2002;40:1675-80.
12. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362:1733-45.
13. Reina J, Padilla E, Alonso F, Ruiz dG, Munar M, Mari M. Evaluation of a new dot blot enzyme immunoassay (directigen flu A+B) for simultaneous and differential detection of influenza a and B virus antigens from respiratory samples. J Clin Microbiol. 2002;40:3515-7.
14. United Kingdom Department of Health. Guidance on the change in HM Treasury discount rates from 6% to 3.5% from 1 April 2003 [cited 2003 Sep 22]. Available from http://www.info.doh.gov.uk/doh/finman.nsf
15. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-72.
16. British National Formulary. BNF 50. 2005 [cited 2006 Oct 10]. Available from http://www.bnf.org/bnf/bnf/current/openat
17. Curtis L, Netten A. Unit costs of health and social care. Canterbury (UK): University of Kent, Personal Social Services Research Unit; 2004.
18. United Kingdom Department of Health Hospital episode statistics. 2005 [cited 2006 Oct 10]. Available from http://www.dh.gov.uk/ PublicationsAndStatistics/Statistics/HospitalEpisodeStatistics/fs/en
19. United Kingdom. Department of Health. NHS reference costs 2004 [cited 2006 Oct 10]. Available from http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_4105545
20. O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health. 2003;6:116-25.
21. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22:4203-14.
22. Kelly H, Birch C. The causes and diagnosis of influenza-like illness. Aust Fam Physician. 2004;33:305-9.
23. Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ. 2005;6:244-52.
24. Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology. 2005;341:102-6.
25. National Institute for Clinical Excellence (NICE). Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. 2003.
26. Her Majesty's Treasury. The green book - appraisal and evaluation in central government. 2003 [cited 2006 Oct 10]. Available from http://www.hm-treasury.gov.uk/economic_data_and_tools/greenbook/ data_greenbook_index.cfm
27. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736-41.
28. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224-7.
29. Woodall J, Rowson KE, McDonald J. Age and Asian influenza, 1957. BMJ. 1958;2:1316-8.
30. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442:448-52.
31. Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans. Lancet. 2006;367:1405-11.
32. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis. 2001;183:523-31.
33. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci. 2001;356:1895-7.
34. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88.
35. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis. 2004;190:1627-30.
36. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother. 2007;51:1414-24.
37. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis [serial on the internet]. 2007 [cited 2007 Dec 1]. Available from http://www.cdc.gov/eid/ content/13/9/1354.htm
38. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Veron M, et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother. 2006;50:3809-15.
39. Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med. 2007;0111-21.